SEC Settles Insider Trading Case: Former Jazz Due Diligence Staffer Made $69K Profit on Chimerix Stock

Context The Securities and Exchange Commission (SEC) recently concluded an insider trading case involving a former Jazz Pharmaceuticals plc staffer, underscoring its enforcement efforts against financial market misconduct. Insider trading, the illegal practice of using non-public, material information to make trading decisions, undermines market fairness and investor confidence. The case centers on a corporate acquisition, a common scenario for such illicit activities.

Key Facts Weizheng Zeng, formerly part of Jazz Pharmaceuticals' due diligence team, acquired 19,902.469 shares of Chimerix, Inc. (CMRX) stock between February 19 and March 4, 2025. This period coincided with his involvement in reviewing Jazz's impending acquisition of Chimerix. The stock purchases were spread across six separate accounts, indicating a calculated effort.

On March 5, 2025, Jazz Pharmaceuticals announced its acquisition of Chimerix. Following this news, Chimerix (CMRX) stock experienced a substantial surge, closing 70.57% higher than its previous day's close. This significant market reaction generated a profit of $69,011 for Zeng on his accumulated shares.

What It Means Zeng has now reached a settlement with the SEC. He agreed to disgorge, or repay, the full $69,011 profit he made from the illegal trades. Additionally, he will pay $2,443.25 in prejudgment interest, which covers the earnings from the time of the trades until the settlement. A civil penalty of $69,011, matching his illicit gains, was also imposed. This settlement highlights the SEC's consistent approach: depriving individuals of ill-gotten gains and imposing financial penalties to deter future misconduct.

This outcome reaffirms the SEC's commitment to protecting market integrity. Employees involved in sensitive corporate transactions, such as mergers and acquisitions, carry a fiduciary duty to their employers and the market not to misuse confidential information. The transparency of public markets depends on all participants having access to information simultaneously. Going forward, market participants will observe continued regulatory vigilance, particularly around high-value corporate events like pharmaceutical mergers.